# A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Source: https://onco.cc/trials/nct05243550/  
OnCo record `nct05243550` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of UGN-102 in bladder & urothelial cancer, run by UroGen Pharma Ltd., active and no longer recruiting.

## Summary

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT05243550 by UroGen Pharma Ltd., with 240 participants enrolled, started 2022-03-01 and due to reach its primary completion in 2023-04-26. Interventions recorded: UGN-102. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05243550
- Phase: 3
- Setting: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
- Sponsor: UroGen Pharma Ltd.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT05243550: https://clinicaltrials.gov/study/NCT05243550

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [UroGen Pharma](https://onco.cc/companies/urogen-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05243550.json